Edition:
United Kingdom

Trevena Inc (TRVN.OQ)

TRVN.OQ on NASDAQ Stock Exchange Global Select Market

0.55USD
16 Jan 2019
Change (% chg)

-- (--)
Prev Close
$0.55
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
687,646
52-wk High
$3.58
52-wk Low
$0.38

Select another date:

Fri, Nov 2 2018

Trevena opioid painkiller fails to win FDA approval, shares plunge

Trevena Inc shares plunged 45 percent on Friday after the U.S. Food and Drug Administration declined to approve its opioid injection for managing acute pain, citing inadequate safety data.

UPDATE 1-Trevena opioid painkiller fails to win FDA approval, shares plunge

Nov 2 Trevena Inc shares plunged 45 percent on Friday after the U.S. Food and Drug Administration declined to approve its opioid injection for managing acute pain, citing inadequate safety data.

Trevena opioid painkiller fails to win FDA approval

Nov 2 Trevena Inc said on Friday the U.S. Food and Drug Administration declined to approve its opioid injection for managing acute pain.

UPDATE 2-Trevena's opioid painkiller fails to get FDA panel backing

Oct 11 Trevena Inc's opioid injection for managing acute pain failed to win the backing of an advisory panel to the Food and Drug Administration on Thursday, against the backdrop of opioid addiction in the United States reaching epidemic proportion.

Trevena's opioid painkiller fails to get FDA panel nod

Oct 11 An advisory panel to the U.S. Food and Drug Administration on Thursday voted against approval of Trevena Inc's opioid injection for managing acute pain.

FDA staff raises safety issues over Trevena opioid injection

Trevena Inc's opioid injection to treat acute pain could be abused and potentially lead to overdose, staff reviewers of the U.S. Food and Drug Administration said on Tuesday, sending the drugmaker's shares down 66 percent.

UPDATE 1-FDA staff raises safety issues over Trevena opioid injection

Oct 9 Trevena Inc's opioid injection to treat acute pain could be abused and potentially lead to overdose, staff reviewers of the U.S. Food and Drug Administration said on Tuesday, sending the drugmaker's shares down 66 percent.

FDA staff raises safety concerns over Trevena opioid drug

Oct 9 Staff reviewers of the U.S. Food and Drug Administration on Tuesday raised safety concerns over Trevena Inc's opioid injection to treat acute pain, saying the treatment has an abuse and overdose potential.

Select another date: